Since Morphic Medical’s founding in 2003, our mission has been to alleviate the symptoms of type 2 diabetes and obesity for patients fighting these global epidemics worldwide. Our revolutionary RESET® therapy is a testament to Morphic Medical’s mission. The first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. Morphic Medical’s aim is to bridge the gap between pharmaceuticals and surgery by providing an alternate treatment option to help reduce HbA1c and weight for individuals who are underserved by drugs and injections, but for whom surgery may not be an option.
Morphic Medical is headquartered in Boston, Massachusetts. Our team of business experts and industry veterans have a successful track record of pioneering and commercializing breakthrough healthcare technologies.
In the U.S. Alone, 1.4 million new cases of Diabetes diagnosed per year.1
Around the world, 6.7 million deaths were due to Diabetes-related causes in 2021.2
More than 95% of people with Diabetes have Type2.3
537 million people are living with Diabetes.4
By 2023, 643 million people will have Diabetes and it will be the 9th leading cause of deaths.5
Morphic Medical is currently enrolling patients for its STEP-1 clinical study of RESET® in the United States. Learn more if you or someone you know are interested in participating in the study and would like to see if you qualify to join.
Learn more
